Refinement of the Clinical Scenario Evaluation Framework for Assessment of Competing Development Strategies with an Application to Multiple Sclerosis

被引:0
|
作者
Tim Friede
Richard Nicholas
Nigel Stallard
Susan Todd
Nicholas Parsons
Elsa Valdés-Márquez
Jeremy Chataway
机构
[1] Warwick Medical School,
[2] The University of Warwick,undefined
[3] Imperial College Healthcare NHS Trust,undefined
[4] Applied Statistics,undefined
[5] University of Reading,undefined
[6] National Hospital for Neurology and Neurosurgery,undefined
[7] University Medical Center Göttingen,undefined
[8] Department of Medical Statistics,undefined
关键词
Clinical scenario evaluation; Drug development program; Clinical development; Adaptive seamless design; Multiple sclerosis;
D O I
暂无
中图分类号
学科分类号
摘要
When competing strategies for development programs, clinical trial designs, or data analysis methods exist, the alternatives need to be evaluated in a systematic way to facilitate informed decision making. Here we describe a refinement of the recently proposed clinical scenario evaluation framework for the assessment of competing strategies. The refinement is achieved by subdividing key elements previously proposed into new categories, distinguishing between quantities that can be estimated from preexisting data and those that cannot and between aspects under the control of the decision maker from those that are determined by external constraints. The refined framework is illustrated by an application to a design project for an adaptive seamless design for a clinical trial in progressive multiple sclerosis.
引用
收藏
页码:713 / 718
页数:5
相关论文
共 50 条
  • [41] Adaptive clinical trials incorporating treatment selection and evaluation: methodology and application in progressive multiple sclerosis
    Nicholas, R.
    Chataway, J.
    Todd, S.
    Stallard, N.
    Valdes-Marquez, E.
    Parsons, N.
    Friede, T.
    MULTIPLE SCLEROSIS, 2009, 15 (09): : S142 - S143
  • [42] Clinical and videonystagmographical evaluation of vestibular manifestations in multiple sclerosis
    El Alaoui El Rhoul, S.
    Ridal, M.
    Ouattassi, N.
    Bouchal, S.
    El Amine El Alami, M.
    Belahssen, M.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 524 - 524
  • [43] Clinical evaluation and follow-up in multiple sclerosis
    Roullet, E
    REVUE NEUROLOGIQUE, 2001, 157 (8-9) : 1121 - 1123
  • [44] CLINICAL EVALUATION OF POSSIBLE ETIOLOGIC FACTORS IN MULTIPLE SCLEROSIS
    ALTER, M
    SPEER, J
    NEUROLOGY, 1968, 18 (02) : 109 - &
  • [45] Clinical evaluation of multiple sclerosis:: quantification by use of scales
    Izquierdo, G
    Ruiz-Peña, JL
    REVISTA DE NEUROLOGIA, 2003, 36 (02) : 145 - 152
  • [46] DELPHI METHOD APPLICATION FOR EVALUATION OF INNOVATIVE PRODUCT DEVELOPMENT SCENARIO
    Tolocka, Eligijus
    Maceika, Augustinas
    ENTREPRENEURSHIP AND SUSTAINABILITY ISSUES, 2024, 11 (03): : 37 - 49
  • [47] Clinical features of the debut and development of multiple sclerosis in Uzbekistan
    Mirzaeva, D.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2019, 405
  • [48] A novel mouse model for the assessment of neuroprotection and repair strategies for multiple sclerosis
    Katie, Lidster
    Jackson, Sam
    Gavin, Giovannoni
    David, Baker
    JOURNAL OF NEUROIMMUNOLOGY, 2010, 228 (1-2) : 38 - 38
  • [49] Assessment of clinical definitions of conversion of relapsing-remitting multiple sclerosis to secondary progressive multiple sclerosis
    Diaz-Cruz, Camilo
    Healy, Brian
    Chua, Alicia
    Bhattacharyya, Shamik
    Kimbrough, Dorlan
    Severson, Christopher
    Stankiewicz, James
    Sattarnezhad, Neda
    Glanz, Bonnie
    Weiner, Howard
    Chitnis, Tanuja
    NEUROLOGY, 2017, 88
  • [50] Multiple sclerosis in children: clinical diagnosis, therapeutic strategies, and future directions
    Banwell, Brenda
    Ghezzi, Angelo
    Bar-Or, Amit
    Mikaeloff, Yann
    Tardieu, Marc
    LANCET NEUROLOGY, 2007, 6 (10): : 887 - 902